Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Kao, Hsiang-Fong [1 ]
Huang, Huai-Cheng [1 ]
Liao, Bin-Chi [1 ]
Hong, Ruey-Long [1 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P273
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck
    Recchia, Francesco
    Candeloro, Giampiero
    Di Staso, Mario
    Necozione, Stefano
    Bisegna, Roberta
    Bratta, Massimo
    Tombolini, Vincenzo
    Rea, Silvio
    [J]. JOURNAL OF IMMUNOTHERAPY, 2008, 31 (04) : 413 - 419
  • [32] Vinorelbine and carboplatin in recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Kornek, V
    Scheithauer, W
    Glaser, C
    Toth, J
    Duman, M
    Formanek, M
    Hejna, M
    Kornfehl, J
    [J]. ONCOLOGY, 1999, 56 (01) : 24 - 27
  • [33] Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma
    Specenier, Pol
    Vermorken, Jan B.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (09) : 901 - 915
  • [34] Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
    Hedberg, Matthew L.
    Goh, Gerald
    Chiosea, Simion I.
    Bauman, Julie E.
    Freilino, Maria L.
    Zeng, Yan
    Wang, Lin
    Diergaarde, Brenda B.
    Gooding, William E.
    Lui, Vivian W. Y.
    Herbst, Roy S.
    Lifton, Richard P.
    Grandis, Jennifer R.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (01): : 169 - 180
  • [35] Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Haddad, Robert, I
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 982 - 984
  • [36] Prognostic significance of metastatic sites in recurrent or metastatic squamous cell carcinoma of the head and neck
    Nishimura, Ari
    Yokota, Tomoya
    Iida, Yoshiyuki
    Kamijo, Tomoyuki
    Mukaigawa, Takashi
    Onozawa, Yusuke
    Todaka, Akiko
    Hamauchi, Satoshi
    Kawakami, Takeshi
    Shirasu, Hiromichi
    Onoe, Tsuyoshi
    Ogawa, Hirohumi
    Kawabata, Takanori
    Yasui, Hirofumi
    Onitsuka, Tetsuro
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S296 - S296
  • [37] Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Lang, Yitian
    Dong, Deshi
    Wu, Bin
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (12) : 1137 - 1146
  • [38] Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Yitian Lang
    Deshi Dong
    Bin Wu
    [J]. Clinical Drug Investigation, 2020, 40 : 1137 - 1146
  • [39] Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
    Yeh, Justin
    Guddati, Achuta Kumar
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (06): : 1821 - 1826
  • [40] A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC).
    Saba, Nabil F.
    Ekpenyong, Asari
    McCook-Veal, Ashley
    Patel, Mihir
    Schmitt, Nicole Cherie
    Stokes, William A.
    Bates, James Edward
    Rudra, Soumon
    Abousaud, Marin Ibrahim
    Muzaffar, Jameel
    Kirtane, Kedar
    Teng, Yong
    Steuer, Conor Ernst
    Shin, Dong Moon
    Liu, Yuan
    Chung, Christine H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345